Zylberberg B, Amiel J P, Jamain B, Pouillart P, Ravina J H, Salat-Baroux J
Nouv Presse Med. 1979 Mar 3;8(10):755-8.
Traditional treatments have proved to be of little effect on inflammatory carcinomas of the breast. The later show a tendency to early metastases and the mean survival is less than 19 months. The preliminary results of the therapeutic protocol reported here and whose originality lies in the primary use of non-specific immunotherapy and of high-dosage chemotherapy appear to be very favourable. The protocol was used in 9 patients. "Thermographic cooling" was taken as the criterion of operability. Initial chemotherapy was restarted after surgery up to a total of 10 courses, and followed by maintenance chemotherapy for one year. Immunotherapy using BCG was routinely associated with the antimitotic agents. After 41 months, the results were as follows: -- local recurrence after tumorectomy in 2 patients (18th and 31st months); these recurrences were controlled by cobalt. -- the other 7 patients show no sign of recurrence. These 9 patients are presently in complete remission.
传统治疗方法已被证明对炎性乳腺癌疗效甚微。后者有早期转移的倾向，平均生存期不到19个月。本文报道的治疗方案的初步结果似乎非常令人满意，该方案的独到之处在于主要使用非特异性免疫疗法和高剂量化疗。该方案用于9例患者。以“热像图降温”作为可手术性的标准。术后重新开始初始化疗，共进行10个疗程，随后进行为期一年的维持化疗。使用卡介苗的免疫疗法常规与抗有丝分裂剂联合使用。41个月后，结果如下：——2例患者（分别在第18个月和第31个月）肿瘤切除术后出现局部复发；这些复发通过钴治疗得到控制。——其他7例患者无复发迹象。这9例患者目前完全缓解。
